A Phase 4 interventional study of KAD-1229 and Placebo in Type 2 Diabetes Mellitus, sponsored by Kissei Pharmaceutical Co., Ltd.. Completed at 1 site in Japan. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2019-09-06.
Sponsored by Kissei Pharmaceutical Co., Ltd. · Phase 4 and Interventional
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 394 studies in Diabetes Mellitus, Type 2 with a site in Japan — 23 open to participants now, 31 under way, 22 of them phase 3. Diabetes Mellitus, Type 2 · Japan.
Among the 394 studies in Diabetes Mellitus, Type 2 with a site in Japan, this one is the 218th largest by enrollment of the 334 interventional ones that give a count, is one of 50 in phase 4, and was the 213th registered.
10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.
Browse Diabetes Mellitus, Type 2 studies →23 of the 394 studies in Diabetes Mellitus, Type 2 with a site in Japan are open now. Recruiting first, the newest first:
Eli Lilly and Company · Sites in Japan, United States, Brazil and 7 more countries
Ages 18+
Eli Lilly and Company · Sites in Japan, United States, Argentina and 1 more country
Ages 18+
AstraZeneca · Sites in Japan, United States, Argentina and 8 more countries
Ages 18+
AstraZeneca · Sites in Japan, United States, Argentina and 13 more countries
Ages 18+
Amgen · Sites in Japan, United States, Canada and 2 more countries
Ages 18–99
A study can be open while its sites in Japan have not opened yet or have stopped. Only those recruiting at a site in Japan →
Of the 883 Diabetes Mellitus, Type 2 studies recruiting now, 374 (42%) set no upper age limit and 383 (43%) stop at 75 or younger; 52 take children under 18; 205 take healthy volunteers.
This study: 20 Years and older · all sexes.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
394 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 37 · Phase 2 52 · Phase 3 194 · Phase 4 50
First in 1999; this study’s year is marked.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 178 is above the median of 80 across 8,359 interventional studies indexed under Diabetes Mellitus, Type 2.
Median enrollment 284 across the 334 interventional studies, 1,869 across the 51 observational. Of the 342 that completed or were terminated, 182 (53%) have results posted.
This tab as a report to print or save as PDF → With an account.
350 of 394 have an industry lead sponsor. The 10 most frequent:
Kissei Pharmaceutical Co., Ltd. is the lead sponsor of 63 studies on the registry; 3 are open to participants now.
Kissei Pharmaceutical Co., Ltd. has 2 studies filed under Diabetes Mellitus, Type 2 — fewer than ten, so there is no comparison to draw.
8 of the studies in Diabetes Mellitus, Type 2 with a site in Japan that are under way reach primary completion within a year, 4 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06858878Phase 3AmgenEfficacy and Safety of Maridebart Cafraglutide in Adult Participants With Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight | 2027-01-21 |
| NCT06987695Phase 3AmgenEfficacy and Safety of Maridebart Cafraglutide in Adult Participants in Japan Who Have Obesity Disease | 2027-04-27 |
| NCT06993792Phase 3Eli Lilly and CompanyA Master Protocol for Orforglipron (LY3502970) in Participants With Obesity or Overweight With and Without Type 2 Diabetes | 2027-08 |
| NCT06972472Phase 3Eli Lilly and CompanyA Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Type 2 Diabetes | 2027-08 |
| NCT06151964AstraZenecaA Trial to Learn How Safe AZD9550 Monotherapy and Combined With AZD6234 is in People With or Without Type 2 Diabetes Who Are Living With Obesity and Overweight | 2027-01-29 |
Add all 8 to your calendar (.ics) → With an account.
Among the 394 studies in Diabetes Mellitus, Type 2 with a site in Japan, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the safety and efficacy of KAD-1229 as combination therapy with insulin for 16 weeks and up to 52 weeks administration in patients with type 2 Diabetes Mellitus who show inadequate glycemic control with diet, and insulin monotherapy, or insulin and oral hypoglycemic agent.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients are administered KAD-1229 for 16 weeks (double-blind period), followed by KAD-1229 for up to 52 weeks (open-label period) with insulin throughout the study.
Drug: KAD-1229 · Drug: Insulin
Patients are administered Placebo for 16 weeks (double-blind period), followed by KAD-1229 for up to 52 weeks (open-label period) with Insulin throughout the study.
Drug: KAD-1229 · Drug: Placebo · Drug: Insulin
Change From Baseline in HbA1c
Time frame: 16 weeks
| Milestone | Placebo/KAD-1229 | KAD-1229/KAD-1229 |
|---|---|---|
| Started | 60 | 118 |
| Completed | 57 | 114 |
| Not completed | 3 | 4 |
| Withdrew: Adverse event | 1 | 2 |
| Withdrew: Lack of efficacy | 1 | 0 |
| Withdrew: Physician decision | 0 | 1 |
| Withdrew: Withdrawal by subject | 1 | 1 |
| Milestone | Placebo/KAD-1229 | KAD-1229/KAD-1229 |
|---|---|---|
| Started | 57 | 113 |
| Completed | 50 | 88 |
| Not completed | 7 | 25 |
| Withdrew: Adverse event | 3 | 4 |
| Withdrew: Lack of efficacy | 4 | 19 |
| Withdrew: Protocol violation | 0 | 1 |
| Withdrew: Withdrawal by subject | 0 | 1 |
| % (value of HbA1c) | Placebo/KAD-1229 | KAD-1229/KAD-1229 |
|---|---|---|
| Change From Baseline in HbA1c | 0.05 ± 1.04 | -0.61 ± 0.87 |
Collected over Placebo/KAD-1229 and KAD-1229/KAD-1229: 16 weeks, KAD-1229: 52 weeks. Non-serious events are listed at a 3% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo/KAD-1229 (Data Through Week 16) | 0/60 (0%) | 2/60 (3.3%) | 19/60 (31.7%) |
| KAD-1229/KAD-1229 (Data Through Week 16) | 0/118 (0%) | 4/118 (3.4%) | 28/118 (23.7%) |
| KAD-1229 (Data Through Week 52) | 0/175 (0%) | 18/175 (10.3%) | 98/175 (56%) |
| Event | Placebo/KAD-1229 (Data Through Week 16) | KAD-1229/KAD-1229 (Data Through Week 16) | KAD-1229 (Data Through Week 52) |
|---|---|---|---|
| Angina pectorisCardiac disorders | 0/60 | 1/118 | 3/175 |
| Myocardial ischaemiaCardiac disorders | 1/60 | 0/118 | 1/175 |
| Pneumonia bacterialInfections and infestations | 1/60 | 0/118 | 0/175 |
| Sick sinus syndromeCardiac disorders | 1/60 | 0/118 | 0/175 |
| Colon cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/60 | 1/118 | 1/175 |
| Metastases to liverNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/60 | 1/118 | 1/175 |
| Pancreatic carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/60 | 1/118 | 1/175 |
| Angina unstableCardiac disorders | 0/60 | 1/118 | 1/175 |
| PneumoniaInfections and infestations | 0/60 | 0/118 | 1/175 |
| Renal cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/60 | 0/118 | 1/175 |
| Event | Placebo/KAD-1229 (Data Through Week 16) | KAD-1229/KAD-1229 (Data Through Week 16) | KAD-1229 (Data Through Week 52) |
|---|---|---|---|
| NasopharyngitisInfections and infestations | 10/60 | 13/118 | 49/175 |
| Cold sweatSkin and subcutaneous tissue disorders | 0/60 | 2/118 | 9/175 |
| HungerGeneral disorders | 1/60 | 2/118 | 9/175 |
| Back painMusculoskeletal and connective tissue disorders | 3/60 | 3/118 | 6/175 |
| AstheniaGeneral disorders | 2/60 | 2/118 | 8/175 |
| DizzinessNervous system disorders | 1/60 | 3/118 | 8/175 |
| Blood triglycerides increasedInvestigations | 1/60 | 2/118 | 8/175 |
| HypoglycaemiaMetabolism and nutrition disorders | 2/60 | 1/118 | 6/175 |
| PalpitationsCardiac disorders | 0/60 | 2/118 | 6/175 |
| BronchitisInfections and infestations | 0/60 | 0/118 | 6/175 |
| Age, Continuous(years) | Placebo/KAD-1229 | KAD-1229/KAD-1229 | Total |
|---|---|---|---|
| Mean | 56.5 ± 11.7 | 59.7 ± 10.3 | 58.6 ± 10.9 |
| Sex: Female, Male(Participants) | Placebo/KAD-1229 | KAD-1229/KAD-1229 | Total |
|---|---|---|---|
| Female | 9 | 39 | 48 |
| Male | 51 | 79 | 130 |
| Race (NIH/OMB)(Participants) | Placebo/KAD-1229 | KAD-1229/KAD-1229 | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 60 | 118 | 178 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 |
| White | 0 | 0 | 0 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 |
| HbA1c(%) | Placebo/KAD-1229 | KAD-1229/KAD-1229 | Total |
|---|---|---|---|
| Mean | 8.54 ± 0.85 | 8.48 ± 0.70 | 8.50 ± 0.75 |
Results were first posted in Sep 2019, 3 years 2 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Mitiglinide
Kissei Pharmaceutical Co., Ltd. →